Evidence method
Level · gp.fundamentals.capex_revenue_ratio
6.95% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Dec 31, 2022
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-23-000005General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-52.18% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
22.88% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
12.43% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
86.49% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-75.68% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
85.12% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
22.23% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History31 statesSelf-history eligible
Jun 30, 20218/9 normalizedLevel 3Sep 30, 20218/9 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/9 normalizedLevel 3Jun 30, 20228/9 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 6.25%
- Current
- 6.95%
- Delta
- 0.70%
- Previous
- -43.62%
- Current
- -52.18%
- Delta
- -8.56%
- Previous
- 40.86%
- Current
- 22.88%
- Delta
- -17.99%
- Previous
- 43.70%
- Current
- 12.43%
- Delta
- -31.26%
- Previous
- 86.19%
- Current
- 86.49%
- Delta
- 0.30%
- Previous
- -97.63%
- Current
- -75.68%
- Delta
- 21.95%
- Previous
- 92.84%
- Current
- 85.12%
- Delta
- -7.72%
- Previous
- 48.47%
- Current
- 22.23%
- Delta
- -26.24%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_INCREASED →Transitioned To · ALNY CASH_GENERATION_DECREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_DECREASED →Transitioned To · ALNY MARGIN_INCREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.